Trending

RE: Capital for Your Business

http://BusinessLoansFundedNow.com

Hi, letting you know that http://BusinessLoansFundedNow.com can find your business a SBA or private loan for $2,000 - $350K Without high credit or collateral. Find Out how much you qualify for here: http://BusinessLoansFundedNow.com/i.php?url=crediblefind.com&id=e74 Minimum requirements include your company being established for at least a year and with current gross revenue of at least 120K. Eligibility and funding can be completed in as fast as 48hrs. Terms are personalized for each business so I suggest applying to find out exactly how much you can get on various terms. This is a free service from a qualified lender and the approval will be based on the annual revenue of your business. These funds are Non-Restrictive, allowing you to spend the full amount in any way you require including business debt consolidation, hiring, marketing, or Absolutely Any Other expense. If you need fast and easy business funding take a look at these programs now as there is limited availability. Click Here: http://BusinessLoansFundedNow.com/i.php?id=e74 Have a great day, The Business Loans Funded Now Team unsubscribe/remove - http://businessloansfundednow.com/r.php?url=crediblefind.com&id=e74 

Shared by: Albert Einstein

Mp3s, Tracks, Music Downloads

http://www.0daymusic.org

https://0daymusic.org/ 

Shared by: Albert Einstein

Treatment options of inflammatory appendiceal masses in adults

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3703180/

Conclusion:
In patients with suspicion of contained appendiceal inflammation, based on a palpable mass or long duration of symptoms, the diagnosis should be confirmed by imaging techniques, especially CT scan. The patient should receive primary nonsurgical treatment with antibiotics and abscess drainage as needed. After successful nonsurgical treatment, no interval appendectomy is indicated in some cases, but the patient should be informed about the risk of recurrence especially in the presence of appendicolith. The risk of missing another underlying condition (cancer or CD) is low, but motivates a follow-up with a colon examination and/or a CT scan or US, especially in patients above the age of 40 years. 

Shared by: Albert Einstein

Which Statin Is Right for My Patient?

http://www.medscape.com/viewarticle/561128

For the dyslipidemic patient, how do we differentiate between the statins; ie, when should one be used preferentially over the other? Are there significant clinical differences among them?

Chemistry
Pharmacokinetics
Potency
Safety
Cost
Pleiotropic Effects  

Shared by: Albert Einstein

Statin Therapy: Risks vs Benefit: An Expert Interview With Eliot A. Brinton, MD

http://www.medscape.org/viewarticle/481357

Conclusion:
As a class, the statins are remarkably safe and their use in patients who need LDL lowering for atheroprevention has a very high benefit/risk ratio. But because they are most commonly used in older patients with complicated health histories, and because of heightened public concerns, we must always remember to address several safety issues when prescribing statins. Although there is increasing impetus toward more and more aggressive lipid-lowering therapy, we need to keep the following always in mind:

1. Safety, cost, and efficacy considerations often point to:
-Use of lower doses of a given statin and/or
-Use of safer statins such as fluvastatin and pravastatin; and
-Use of other agents (ezetimibe, niacin, fibrates, and/or sequestrants) in combination with statins for greater LDL-lowering and/or other lipid benefits

2. When starting statins, patients must always be informed of potential safety risks, and any symptoms or signs of adverse effects must be taken seriously and handled properly.  

Shared by: Albert Einstein

Statins in the Treatment of Dyslipidemia in the Presence of Elevated Liver Aminotransferase Levels

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2848423/

The beneficial role of statins in primary and secondary prevention of coronary heart disease has resulted in their frequent use in clinical practice. However, safety concerns, especially regarding hepatotoxicity, have driven multiple trials, which have demonstrated the low incidence of statin-related hepatic adverse effects. The most commonly reported hepatic adverse effect is the phenomenon known as transaminitis, in which liver enzyme levels are elevated in the absence of proven hepatotoxicity. This class effect is usually asymptomatic, reversible, and dose-related. However, the increasing incidence of chronic liver diseases, including nonalcoholic fatty liver disease and hepatitis C, has created a new challenge when initiating statin treatment in patients with high cardiovascular risk. These diseases result in abnormally high liver biochemistry values, discouraging statin use by clinicians, fostering treatment discontinuation, and leaving a large number of at-risk patients untreated. A PubMed/MEDLINE search of the literature regarding statin safety (January 1, 1994-December 31, 2008) was performed, using the following search terms: statin safety, statin-related hepatotoxicity, and chronic liver disease and statin use, as well as the specific names of different statins and different liver diseases. Relevant clinical trials, review articles, panel discussions, and guideline recommendations were selected. This review supports the use of statin treatment in patients with high cardiovascular risk whose elevated aminotransferase levels have no clinical relevance or are attributable to known stable chronic liver conditions. For each patient, the decision should be based on an individual assessment of risks and benefits. 

Shared by: Albert Einstein

AHA/ACC Guideline on the Management of Lower Extremity Peripheral Artery Disease

http://www.acc.org/latest-in-cardiology/ten-points-to-remember/2016/11/10/21/41/sunday-8am-2016-aha-acc-guideline-on-lepad-aha-2016

The following are key points to remember from this Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease (PAD) 

Shared by: Albert Einstein

Vitalik Buterin explains Ethereum

https://www.youtube.com/watch?v=TDGq4aeevgY

3 minute explanation of Ethereum by inventor Vitalik Buterin.

Ethereum is a platform that makes it possible for any developer to write and distribute next-generation decentralized applications.

Borrowing the concept of distributed consensus and cryptographic proof that makes cryptocurrencies such as Bitcoin so effective in trustless payments, Ethereum extends the use of these technologies to trustless agreements. This allows developers to easily build innovative new products on a censorship and collusion-resistant foundation. 

Shared by: Albert Einstein

Ethereum | Future of the Internet

https://www.youtube.com/watch?v=NgJkC3UC4c4

What is Ethereum and decentralised applications? 

Shared by: Albert Einstein

How the blockchain is changing money and business

https://www.youtube.com/watch?v=Pl8OlkkwRpc

What is the blockchain? If you don't know, you should; if you do, chances are you still need some clarification on how it actually works. Don Tapscott is here to help, demystifying this world-changing, trust-building technology which, he says, represents nothing less than the second generation of the internet and holds the potential to transform money, business, government and society. 

Shared by: Albert Einstein